Chesko JD - Search Results

1

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.

Fox CB, Barnes V L, Evers T, Chesko JD, Vedvick TS, Coler RN, Reed SG, Baldwin SL. Fox CB, et al. Among authors: chesko jd. Influenza Other Respir Viruses. 2013 Sep;7(5):815-26. doi: 10.1111/irv.12031. Epub 2012 Nov 5. Influenza Other Respir Viruses. 2013. PMID: 23122325 Free PMC article.

2

Modulating potency: Physicochemical characteristics are a determining factor of TLR4-agonist nanosuspension activity.

Dowling QM, Sivananthan SJ, Guderian JA, Moutaftsi M, Chesko JD, Fox CB, Vedvick TS, Kramer RM. Dowling QM, et al. Among authors: chesko jd. J Pharm Sci. 2014 Mar;103(3):879-89. doi: 10.1002/jps.23868. Epub 2014 Jan 24. J Pharm Sci. 2014. PMID: 24464844

3

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations.

Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, Poshusta GR, Chesko J, Coler RN, Friede M, Reed SG, Vedvick TS. Anderson RC, et al. Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):123-32. doi: 10.1016/j.colsurfb.2009.08.022. Epub 2009 Aug 20. Colloids Surf B Biointerfaces. 2010. PMID: 19748238

4

Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B.

Singh M, Kazzaz J, Chesko J, Soenawan E, Ugozzoli M, Giuliani M, Pizza M, Rappouli R, O'Hagan DT. Singh M, et al. J Pharm Sci. 2004 Feb;93(2):273-82. doi: 10.1002/jps.10538. J Pharm Sci. 2004. PMID: 14705185

5

The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles.

Malyala P, Chesko J, Ugozzoli M, Goodsell A, Zhou F, Vajdy M, O'Hagan DT, Singh M. Malyala P, et al. J Pharm Sci. 2008 Mar;97(3):1155-64. doi: 10.1002/jps.21065. J Pharm Sci. 2008. PMID: 17683059

6

An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles.

Chesko J, Kazzaz J, Ugozzoli M, O'hagan DT, Singh M. Chesko J, et al. J Pharm Sci. 2005 Nov;94(11):2510-9. doi: 10.1002/jps.20472. J Pharm Sci. 2005. PMID: 16200615

7

A practical approach to the use of nanoparticles for vaccine delivery.

Wendorf J, Singh M, Chesko J, Kazzaz J, Soewanan E, Ugozzoli M, O'Hagan D. Wendorf J, et al. J Pharm Sci. 2006 Dec;95(12):2738-50. doi: 10.1002/jps.20728. J Pharm Sci. 2006. PMID: 16927245

8

Charged polylactide co-glycolide microparticles as antigen delivery systems.

Singh M, Kazzaz J, Ugozzoli M, Chesko J, O'Hagan DT. Singh M, et al. Expert Opin Biol Ther. 2004 Apr;4(4):483-91. doi: 10.1517/14712598.4.4.483. Expert Opin Biol Ther. 2004. PMID: 15102598 Review.

9

Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.

Singh M, Chesko J, Kazzaz J, Ugozzoli M, Kan E, Srivastava I, O'Hagan DT. Singh M, et al. Pharm Res. 2004 Dec;21(12):2148-52. doi: 10.1007/s11095-004-7666-6. Pharm Res. 2004. PMID: 15648244

10

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens.

Singh M, Ugozzoli M, Kazzaz J, Chesko J, Soenawan E, Mannucci D, Titta F, Contorni M, Volpini G, Del Guidice G, O'Hagan DT. Singh M, et al. Vaccine. 2006 Mar 6;24(10):1680-6. doi: 10.1016/j.vaccine.2005.09.046. Epub 2005 Oct 6. Vaccine. 2006. PMID: 16300864

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters